AGEN - アジェナス （Agenus Inc.） アジェナスAGENのチャート
AGENの企業情報
| symbol | AGEN |
|---|---|
| 会社名 | Agenus Inc （アジェナス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アジェナス（Agenus Inc.）は免疫腫瘍学（I-O）会社である。同社は癌と戦うために身体の免疫システムに関わる治療法の発見と開発に従事する。同社は、ヒト抗体を産生するように設計されたレトロサイトディスプレイ、SECANT酵母ディスプレイおよびファージディスプレイ技術を含む抗体発見プラットフォーム、チェックポイントモジュレーター（CPM）プログラムを含む抗体候補プログラム、並びにProphage、AutoSynVax、PhosPhoSynVax及びQS-21スチムロンアジュバント（QS-21スチムロン）を主とするサポニンベースのワクチンアジュバントを含むワクチンプログラムなどのプラットフォームとプログラムによって駆動されるI-Oポートフォリオを開発している。同社の発見パイプラインには、一連のチェックポイント変調（CPM）抗体が含まれる。ワクチンプラットフォームには、その熱ショックタンパク質（HSP）ベースのプロファージワクチン候補、およびその合成ワクチン候補のASVとPSVが含まれる。 アジェナスは米国のバイオ医薬品メ―カ―。主に、がん治療を目的に、免疫システム機能を調節するチェックポイント調節因子を標的とした抗体医薬品の発見、開発、商用化に従事。脳腫瘍、腎臓がん、肺がん、アルツハイマ―などの免疫治療用ワクチンの研究を行う。本社はマサチュ―セッツ州。 Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. |
| 本社所在地 | 3 Forbes Road Lexington MA 02421 USA |
| 代表者氏名 | Garo H. Armen ガロ・アーメン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer Founder |
| 電話番号 | +1 781-674-4410 |
| 設立年月日 | 1994年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2000年 |
| 従業員数 | 255人 |
| url | www.agenusbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/agen |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -113.91800 |
| 終値（lastsale） | 2.07 |
| 時価総額（marketcap） | 234493980.12 |
| 時価総額 | 時価総額（百万ドル） 223.16580 |
| 売上高 | 売上高（百万ドル） 29.24434 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 193.05562 |
| 当期純利益 | 当期純利益（百万ドル） -150.89400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Agenus Inc revenues decreased 44% to $17.5M. Net loss applicable to common stockholders increased 61% to $78.9M. Revenues reflect Revenue (research and development) decrease of 61% to $12.1M. Higher net loss reflects Non-operating income (expense) decrease from $2.4M (income) to $1.4M (expense) GENERAL AND ADMINISTRATIVE increase of 23% to $16.3M (expense). |
AGENのテクニカル分析
AGENのニュース
Agenus (AGEN) Q1 2023 Earnings Call Transcript 2023/05/09 23:00:34 The Motley Fool
AGEN earnings call for the period ending March 31, 2023.
Agenus Inc. (AGEN) Q1 2023 Earnings Call Transcript 2023/05/09 15:33:10 Seeking Alpha
Agenus Inc. (NASDAQ:NASDAQ:AGEN) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ETCompany ParticipantsZack Armen - Head, IRDr.
Agenus stock wins FDA fast track tag for colorectal cancer therapy 2023/04/17 12:21:48 Seeking Alpha
Agenus (AGEN) announced Monday that the FDA granted Fast Track Designation for a combination therapy containing botensilimab (AGEN1181) and balstilimab. Read more here.
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics 2023/03/30 12:41:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc. (“MiNK”), to shareholders of Agenus as of April 17, 2023 (the “Record Date”). MiNK is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T c
Agenus'' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer 2023/03/27 17:12:11 Benzinga
Agenus Inc (NASDAQ: AGEN ) announced results from a cohort of 24 evaluable patients in an expansion of its Phase 1b study of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) in patients with recurrent platinum-resistant/refractory ovarian cancer. These findings showed a 33% overall response rate (ORR). Other PD-(L)1 + CTLA-4 combinations in other trials reported 3-10% response … Full story available on Benzinga.com
Let Me Show You The Secrets Of: Agenus Inc. (NASDAQ:AGEN -5.43%), Compass, Inc. (NYSE:COMP -3.27%) 2023/03/08 11:05:48 Stock Equity
AGEN has seen its SMA50 which is now -27.07%. In looking the SMA 200 we see that the stock has seen a -27.64%. COMP has seen its SMA50 which is … The post Let Me Show You The Secrets Of: Agenus Inc. (NASDAQ:AGEN -5.43%), Compass, Inc. (NYSE:COMP -3.27%) appeared first on Stocks Equity .
Intriguing stocks: Agenus Inc. (NASDAQ:AGEN), MP Materials Corp. (NYSE:MP) 2023/03/03 08:08:34 Stock Equity
AGEN has seen its SMA50 which is now -19.60%. In looking the SMA 200 we see that the stock has seen a -19.18%. MP has seen its SMA50 which is … The post Intriguing stocks: Agenus Inc. (NASDAQ:AGEN), MP Materials Corp. (NYSE:MP) appeared first on Stocks Equity .
Agenus Inc. (NASDAQ:AGEN), Delek US Holdings, Inc. (NYSE:DK) – Eye-popping stocks 2023/03/01 12:52:29 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Agenus Inc. (NASDAQ:AGEN), Delek US Holdings, Inc. (NYSE:DK) – Eye-popping stocks appeared first on Stocks Equity .
Observations on the Agenus Inc. (NASDAQ:AGEN) Growth Curve 2023/02/28 18:00:00 US Post News
Agenus Inc. (AGEN)’s stock has witnessed a price hike of 4.06% from the previous close with its current price standing at $2.05. Its current price is -39.17% under its 52-week high of $3.37 and 64.00% more than its 52-week low of $1.25. Based on the past 30-day period, the stock price is -23.94% below the […]
Current Stocks’s Volume Buzz: Agenus Inc. (NASDAQ:AGEN), Cinedigm Corp. (NASDAQ:CIDM) 2023/02/24 18:16:16 Stock Equity
AGEN has seen its SMA50 which is now -18.73%. In looking the SMA 200 we see that the stock has seen a -16.17%. CIDM has seen its SMA50 which is … The post Current Stocks’s Volume Buzz: Agenus Inc. (NASDAQ:AGEN), Cinedigm Corp. (NASDAQ:CIDM) appeared first on Stocks Equity .
Let Me Show You The Secrets Of: Agenus Inc. (NASDAQ:AGEN -5.43%), Compass, Inc. (NYSE:COMP -3.27%) 2023/03/08 11:05:48 Stock Equity
AGEN has seen its SMA50 which is now -27.07%. In looking the SMA 200 we see that the stock has seen a -27.64%. COMP has seen its SMA50 which is … The post Let Me Show You The Secrets Of: Agenus Inc. (NASDAQ:AGEN -5.43%), Compass, Inc. (NYSE:COMP -3.27%) appeared first on Stocks Equity .
Intriguing stocks: Agenus Inc. (NASDAQ:AGEN), MP Materials Corp. (NYSE:MP) 2023/03/03 08:08:34 Stock Equity
AGEN has seen its SMA50 which is now -19.60%. In looking the SMA 200 we see that the stock has seen a -19.18%. MP has seen its SMA50 which is … The post Intriguing stocks: Agenus Inc. (NASDAQ:AGEN), MP Materials Corp. (NYSE:MP) appeared first on Stocks Equity .
Agenus Inc. (NASDAQ:AGEN), Delek US Holdings, Inc. (NYSE:DK) – Eye-popping stocks 2023/03/01 12:52:29 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Agenus Inc. (NASDAQ:AGEN), Delek US Holdings, Inc. (NYSE:DK) – Eye-popping stocks appeared first on Stocks Equity .
Observations on the Agenus Inc. (NASDAQ:AGEN) Growth Curve 2023/02/28 18:00:00 US Post News
Agenus Inc. (AGEN)’s stock has witnessed a price hike of 4.06% from the previous close with its current price standing at $2.05. Its current price is -39.17% under its 52-week high of $3.37 and 64.00% more than its 52-week low of $1.25. Based on the past 30-day period, the stock price is -23.94% below the […]
Current Stocks’s Volume Buzz: Agenus Inc. (NASDAQ:AGEN), Cinedigm Corp. (NASDAQ:CIDM) 2023/02/24 18:16:16 Stock Equity
AGEN has seen its SMA50 which is now -18.73%. In looking the SMA 200 we see that the stock has seen a -16.17%. CIDM has seen its SMA50 which is … The post Current Stocks’s Volume Buzz: Agenus Inc. (NASDAQ:AGEN), Cinedigm Corp. (NASDAQ:CIDM) appeared first on Stocks Equity .